Primary and metastatic rhabdomyosarcoma in the breast: neoplasms of adolescent females, a report from the Intergroup Rhabdomyosarcoma Study.
The occurrence of rhabdomyosarcoma (RMS) primary in or metastatic to breast has been regarded as an uncommon event, associated with an unfavorable outcome. Records of 26 patients with diagnoses of breast RMS, either primary or secondary, entered in the Intergroup Rhabdomyosarcoma Study (IRS) (1972-1992) were reviewed and compared with data regarding 47 similar patients in published reports. Of the 26 IRS cases, the histologic subtype was alveolar in 24, embryonal in 1, and not determined in 1. All were female with ages ranging from 11.5 to 20.2 years (median, 15.2 years; mode, 14-16 years). This compact age distribution of both primary (n = 7) and metastatic (n = 19) breast RMS was seen in previously reported series. Among the 19 cases of RMS with initial dissemination to breast, primary tumor sites, were extremity (n = 8), nasopharynx/paranasal sinuses (n = 7), and trunk (n = 4). IRS treatment was risk-based according to site and extent of disease. Four of 7 patients with primary RMS remain disease free 2.9 to 7 years post diagnosis. Among 19 patients with RMS initially metastatic to breast, including 7 in IRS clinical group IV at original diagnosis, three are disease free at 7.6, 15.7 and 17.0 years.


CONCLUSIONS
primary or metastatic RMS in breast is almost confined to adolescent females having tumors with alveolar histology. Approximately one-half of the patients with primary breast disease and 15% of those with metastatic breast disease as an initial recurrence are long-term survivors.
Hays
D M
DM
Department of Surgery, Children's Hospital of Los Angeles, California 90054, USA.
Donaldson
S S
SS
Shimada
H
H
Crist
W M
WM
Newton
W A
WA
Andrassy
R J
RJ
Wiener
E
E
Green
J
J
Triche
T
T
Maurer
H M
HM
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D001943:Breast Neoplasms / Q000473:pathology* / Q000556:secondary; D002648:Child; D018572:Disease-Free Survival; D005121:Extremities / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D009303:Nasopharyngeal Neoplasms / Q000473:pathology; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D010255:Paranasal Sinus Neoplasms / Q000473:pathology; D012189:Retrospective Studies; D012208:Rhabdomyosarcoma / Q000473:pathology* / Q000556:secondary; D018232:Rhabdomyosarcoma, Alveolar / Q000473:pathology / Q000556:secondary; D018233:Rhabdomyosarcoma, Embryonal / Q000473:pathology / Q000556:secondary; D015996:Survival Rate; D013899:Thoracic Neoplasms / Q000473:pathology; D016896:Treatment Outcome